Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVIVE azithromycin prophylaxis trial in adults with advanced HIV disease
PACTR202302799565020Phase 3Recruiting
- Sponsor
- Population Health Research Institute
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing Azithromycin prophylaxis with Placebo comparator (2 arms). Primary endpoint: All-cause mortality at 24 weeks after randomisation. Started Feb 2023; status: recruiting.
02
Drugs
azithromycin
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR202302799565020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202302799565020.